ORIC Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de ORIC Pharmaceuticals es Jacob Chacko , nombrado en May 2018, tiene una permanencia de 6.5 años. compensación anual total es $3.15M, compuesta por 18.9% salario y 81.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.03% de las acciones de la empresa, por valor de $6.99M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 4.6 años, respectivamente.
Información clave
Jacob Chacko
Chief Executive Officer (CEO)
US$3.2m
Compensación total
| Porcentaje del salario del CEO | 18.9% |
| Permanencia del CEO | 6.5yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 4.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Aug 21
ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
Jul 29ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Jul 17We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
May 08ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01
Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$120m |
| Jun 30 2024 | n/a | n/a | -US$111m |
| Mar 31 2024 | n/a | n/a | -US$102m |
| Dec 31 2023 | US$3m | US$596k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$4m | US$572k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$91m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$7m | US$536k | -US$79m |
| Sep 30 2021 | n/a | n/a | -US$84m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$81m |
| Dec 31 2020 | US$6m | US$489k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$672k | US$456k | -US$27m |
| Dec 31 2018 | US$2m | US$290k | -US$21m |
Compensación vs. Mercado: La compensación total ($USD3.15M) de Jacob está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.18M).
Compensación vs. Ingresos: La compensación de Jacob ha sido consistente con los resultados de la empresa en el último año.
CEO
Jacob Chacko (45 yo)
6.5yrs
Permanencia
US$3,153,083
Compensación
Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$186.87k | 0.32% $ 2.2m | |
| President | 6.5yrs | US$3.15m | 1.03% $ 7.0m | |
| Chief Financial Officer | 5.2yrs | US$1.45m | 0.12% $ 803.8k | |
| Chief Medical Officer | 6.2yrs | US$1.51m | 0.034% $ 228.3k | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chief Scientific Officer | 5.3yrs | sin datos | sin datos | |
| General Counsel | 4.6yrs | sin datos | sin datos | |
| VP & Head of People | 2.2yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 5.7yrs | sin datos | sin datos | |
| Chief Business Officer | 6yrs | sin datos | sin datos | |
| Senior VP of Commercial & Medical Affairs | less than a year | sin datos | sin datos |
5.3yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ORIC es experimentado (5.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$186.87k | 0.32% $ 2.2m | |
| President | 6.5yrs | US$3.15m | 1.03% $ 7.0m | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3yrs | US$140.37k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$133.87k | 0.029% $ 196.6k | |
| Independent Director | 4.8yrs | US$147.87k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$141.37k | 0% $ 0 |
4.6yrs
Permanencia media
62.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ORIC se considera experimentada (4.6 años de antigüedad promedio).